STATURE: A Prospective Observational Study of the relationShip beTween Oral DMT bURden and adhErence in People With MS
Latest Information Update: 20 Dec 2022
Price :
$35 *
At a glance
- Drugs Cladribine (Primary) ; Dimethyl fumarate (Primary) ; Diroximel-fumarate (Primary) ; Fingolimod (Primary) ; Ozanimod (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms STATURE
- 20 Dec 2022 New trial record
- 28 Oct 2022 Results (n=91) of a preliminary baseline data analysis assessing differences in DMT satisfaction at time of initiation presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis